Darcy Lewis

Superior progression-free survival (PFS) was seen in patients with ovarian cancer who previously had a partial response (PR) to platinum-based therapy when they took Zejula (niraparib). This response was seen in patients with or without germline BRCA mutations, according to data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

Biomarkers have value in the diagnosis and monitoring of bladder cancer, but their use is still being perfected.

Patients with relapsed serous ovarian cancer saw a survival benefit with Lynparza (olaparib) in a phase 2 trial.

Pretreated patients with recurrent ovarian cancer had a 2.5-month progression-free survival benefit when receiving fosbretabulin plus Avastin compared with Avastin alone; however, hypertension rates doubled.

Treatment with Avastin plus chemotherapy resulted in an improvement in overall survival of nearly five months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage 3/4 ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not, according to an open-label phase 2 trial.